Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
复制标题
DOI：
10.1155/2018/9282646
复制
发表时间：
2018
影响因子：
--
通讯作者：
Wu B
中科院分区：
文献类型：
--
作者：
Ye M;Lu J;Yang F;Wu B
长期芳香化酶抑制剂（AI）治疗有望改善早期乳腺癌的健康结果，但卫生资源消耗较高。本研究的目的是评估来曲唑治疗健康资源有限的绝经后雌激素受体阳性早期乳腺癌妇女的成本效益。 一个马尔可夫模型的开发项目的基础上的早期乳腺癌的临床过程的终身成果。临床和效用数据来自报告的结果。从中国医疗保健的角度估计了成本。测量质量调整生命年（QALY）和增量成本-效果比（ICER）。进行了概率敏感性和单因素分析。 与他莫昔芬治疗5年相比，来曲唑AI治疗5年改善了QALY（10.44 vs. 10.84），并增加了终身成本（CNY ¥ 13，613 vs. CNY ¥ 28，797），导致ICER为CNY ¥ 38，092/QALY。来曲唑治疗5年与他莫昔芬治疗2-3年，然后来曲唑治疗的ICER为CNY ¥ 68，233/QALY。敏感性分析表明，开始辅助内分泌治疗的年龄是最有影响力的参数。 在卫生资源有限的情况下，与他莫昔芬相比，来曲唑辅助内分泌治疗是早期乳腺癌女性的一种成本效益策略。
Long-term aromatase inhibitor (AI) therapy is expected to improve the health outcomes with high health resource consumption in early breast cancer. The aim of the study was to assess the cost-effectiveness of letrozole for postmenopausal women with estrogen receptor positive early breast cancer in a health resource-limited setting. A Markov model was developed to project the lifetime outcomes based on the clinical course of early breast cancer. The clinical and utility data were derived from reported results. Costs were estimated from the perspective of Chinese health care. The quality-adjusted life-year (QALY) and incremental cost-effective ratio (ICER) were measured. Probabilistic sensitivity and one-way analyses were conducted. Compared to 5 years of tamoxifen therapy, 5 years of AI treatment with letrozole improved the QALYs (10.44 versus 10.84) and increased the lifetime costs (CNY ¥13,613 versus CNY ¥28,797), resulting in an ICER of CNY ¥38,092 /QALY. The ICER of 5 years of letrozole versus 2–3 years of tamoxifen and then letrozole was CNY ¥68,233 /QALY. Sensitivity analyses showed that the age of initiating adjuvant endocrine therapy was the most influential parameter. In health resource-limited settings, adjuvant endocrine therapy with letrozole is a cost-effective strategy compared to tamoxifen in women with early breast cancer.
登录
查看更多内容
DOI：
10.3760/cma.j.issn.0254-6450.2016.07.013
发表时间：
2016-07-01
影响因子：
--
作者：
Wang, L;Zhang, Y;Dai, M
通讯作者：
Dai, M
影响因子：
6.2
作者：
Kwon, Janice S.;Sun, Charlotte C.;Lu, Karen H.
通讯作者：
Lu, Karen H.
影响因子：
3.8
作者：
Lee, Sang Gyu;Jee, Young Geon;Seo, Jae Hong
通讯作者：
Seo, Jae Hong
影响因子：
3.8
作者：
Bai, Yongrui;Ye, Ming;Wu, Bin
通讯作者：
Wu, Bin
影响因子：
3.6
作者：
Hu, Bo;Fu, Alex Z.
通讯作者：
Fu, Alex Z.